<DOC>
	<DOCNO>NCT02877082</DOCNO>
	<brief_summary>This phase II trial study well tacrolimus , bortezomib , anti-thymocyte globulin ( thymoglobulin ) work prevent low toxicity graft versus host disease ( GVHD ) patient blood cancer undergo donor stem cell transplant . Tacrolimus anti-thymocyte globulin may reduce risk recipient 's body reject transplant suppress recipient 's immune system . Giving bortezomib transplant may help prevent GVHD stop donor 's cell attack recipient . Giving tacrolimus , bortezomib , anti-thymocyte globulin may better way prevent low toxicity GVHD patient blood cancer undergo donor stem cell transplant .</brief_summary>
	<brief_title>Tacrolimus , Bortezomib , &amp; Thymoglobulin Preventing Low Toxicity GVHD Donor Blood Stem Cell Transplant Patients</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine composite end point alive severe acute GVHD free 6 month follow human leukocyte antigen ( HLA ) match related unrelated donor hematopoietic peripheral blood transplant patient hematologic malignancy receive immunosuppressive combination tacrolimus , bortezomib , anti-thymocyte globulin ( TBT ) GVHD prophylaxis . II . To determine safety combination first six month post-transplant . SECONDARY OBJECTIVES : I . To determine cumulative incidence grade III-IV aGVHD . II . To determine incidence severity chronic GVHD . III . To determine disease relapse progression overall disease free survival one year . OUTLINE : Patients receive tacrolimus intravenously ( IV ) day -3 day 180 . Patients may receive tacrolimus orally ( PO ) later doctor 's discretion . Patients receive anti-thymocyte globulin IV day -3 , -2 , -1 bortezomib IV day 0 day 3 . Patients undergo allogeneic bone marrow transplant day 0 . After completion study treatment , patient follow 6 month periodically 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients acute leukemia , chronic myelogenous leukemia , myeloproliferative disorder myelodysplasia circulate blast le 5 % blast bone marrow within 4 week start transplant conditioning regimen Patients chronic lymphocytic leukemia/small lymphocytic lymphoma ; follicular , marginal zone , diffuse large Bcell mantle cell lymphoma chemosensitive disease time transplant Patients must relate unrelated peripheral blood stem cell donor ; sibling donor must 6/6 match human leukocyte antigen ( HLA ) A B intermediate ( high ) resolution , DRB1 high resolution use deoxyribonucleic acid ( DNA ) base typing , must willing donate peripheral blood stem cell meet institutional criterion donation ; unrelated donor must 8/8 match HLAA , B , C DRB1 high resolution use DNAbased typing ; unrelated donor must willing donate peripheral blood stem cell medically eligible donate stem cell accord National Marrow Donor Program ( NMDP ) criteria Cardiac function : ejection fraction &gt; 40 % Estimated creatinine clearance great 50 mL/minute ( use CockcroftGault formula actual body weight ) Pulmonary function : carbon monoxide diffuse capability test ( DLCO ) ≥ 40 % ( adjust hemoglobin ) force expiratory volume 1 second ( FEV1 ) ≥ 50 % Total bilirubin &lt; 1.5 x upper limit normal ; patient diagnose Gilbert 's disease allow exceed define bilirubin value 1.5 x upper limit normal Alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) &lt; 2.5 x upper normal limit Female subject ( unless postmenopausal least 1 year screen visit , surgically sterilize ) , agree practice two effective method contraception agree completely abstain heterosexual intercourse time sign informed consent 12 month posttransplant Male subject ( even surgically sterilize ) , partner woman childbearing potential must agree practice effective barrier contraception abstain heterosexual intercourse time sign informed consent 12 month posttransplant Signed informed consent Prior allogeneic transplant Karnofsky performance score &lt; 70 % Active central nervous system ( CNS ) involvement malignant cell Patients uncontrolled bacterial , viral , fungal infection ( currently take medication progression clinical improvement ) time enrollment Patients transform lymphoma ( e.g. , Richter 's transformation arise follicular lymphoma chronic lymphocytic leukemia ) Patients seropositive human immunodeficiency virus ( HIV ) Patient active hepatitis B C Patients hypersensitivity bortezomib , boron , mannitol Patients &gt; grade 2 sensory peripheral neuropathy Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality ; prior study entry , electrocardiography ( ECG ) abnormality screen must document investigator medically relevant Female patient lactate pregnant Patients serious medical psychiatric illness likely interfere participation clinical study Patients prior malignancy , except resect basal cell carcinoma treat cervical carcinoma situ ; cancer treat curative intent &gt; 5 year previously allow ; cancer treat curative intent &lt; 5 year previously allow unless approve protocol officer one protocol chair</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>